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Objective: To assess the effect of nebivolol, a highly selective third generation β1-adrenoceptor 
antagonist with an endothelium-dependent vasodilatory action, on smoking-induced endothelial 
dysfunction.
Research design and methods: This open-label study examined the effect of 14 daily 
doses of 5 mg nebivolol on forearm blood ﬂ  ow in 21 healthy, young, male, light smokers 
(5 cigarettes/day), measured by plethysmography on Days 1, 7, and 14. The primary endpoint 
was the difference in forearm blood ﬂ  ow after smoking one standard cigarette from baseline 
(Day 1) until treatment end on Day 14. Secondary outcomes included the difference in forearm 
blood ﬂ  ow between Day 1 and Day 7 compared with Day 14 before and after smoking, the effect 
of nebivolol on blood coagulation parameters, high-sensitive-C-reactive protein (hs-CRP), and 
the safety and tolerability of nebivolol.
Results: Nebivolol for 14 days did not signiﬁ  cantly affect forearm blood ﬂ  ow after smoking. 
On Day 7 of nebivolol treatment, forearm blood ﬂ  ow after smoking was signiﬁ  cantly greater 
than blood ﬂ  ow before smoking (increase of 0.44 mL/min; p = 0.00656). Serum level of hs-CRP 
showed a marked decrease from Day 1 to Day 14. No changes in coagulation parameters were 
observed over the course of nebivolol treatment. Nebivolol was well tolerated throughout the 
study.
Conclusions: The increase in forearm blood ﬂ  ow and the marked decrease in hs-CRP over 
14 days of treatment suggest that nebivolol has a positive effect on endothelial function in light 
smokers, but larger studies are required to conﬁ  rm these observations.
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Introduction
The endothelium is responsible for the synthesis of the potent vasodilator nitric 
oxide (NO). NO is involved in a large number of cardiovascular processes, and NO 
deﬁ  ciency represents an important determinant of cardiovascular risk (Moncada 
and Higgs 2006). Endothelial dysfunction and the associated reduced synthesis or 
action of NO may lead to vasoconstriction, elevated blood pressure and thrombus 
formation, and can ultimately result in atherosclerosis (Brunner et al 2005; Moncada 
and Higgs 2006).
Cigarette smoking is a major modiﬁ  able risk factor for atherosclerosis and periph-
eral artery disease (Lu and Creager 2004). The pathophysiology of these potentially 
fatal diseases has been linked, at least in part, to cigarette-induced increases in oxidative 
stress. By enhancing the production of superoxide and other reactive oxygen species, 
cigarette smoke inactivates NO within the vasculature, thereby disrupting endothelial 
function (Cai and Harrison 2000). Indeed, long-term smokers show markedly impaired 
endothelium-dependent vasodilation, demonstrated in, for example, the brachial artery, Vascular Health and Risk Management 2008:4(4) 910
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which is consistent with endothelial dysfunction (Celermajer 
et al 1993). Smoking cessation has been shown to drastically 
improve endothelial function by limiting vascular endothelial 
damage as well as improving lipid proﬁ  le and decreasing 
thrombotic tendency (Eagles and Martin 1998).
Smoking is also associated with increased levels of 
C-reactive protein (CRP) (Kao et al 2006). Recent research 
has conﬁ  rmed a role for CRP in cardiovascular risk prediction 
(Willerson and Ridker 2004), and CRP has also been directly 
been involved in endothelial dysfunction in experimental 
models (Wilson et al 2006). Serum CRP level, as well as 
representing a marker of inﬂ  ammation, is also, therefore, a 
valid means of quantifying endothelial dysfunction.
Nebivolol is the newest third-generation cardioselective 
beta-blocker with vasodilator activity. In addition to its 
conventional antihypertensive effect, nebivolol also has an 
endothelium-dependent vasodilatory action that may slow or 
prevent some of the vascular complications associated with 
hypertension, and may be of particular beneﬁ  t in patients with 
impaired endothelial function (eg, diabetes, hypercholester-
olemia, or ischemic heart disease) (Cockcroft 2004). A recent 
study showed that the treatment of hypertensive patients, 
concomitantly suffering from type-2 diabetes, with nebivolol 
not only reduced systolic and diastolic blood pressure, but 
also improved metabolic parameters (eg, HbA1c) and physi-
cal capability of those patients (Schmidt et al 2007).
The vasodilatory effect of nebivolol is thought to derive 
from its ability to stimulate NO production by endothelial 
cells (Broeders et al 2000). Infusion of nebivolol into the 
brachial artery has been shown to increase forearm blood 
ﬂ  ow in normotensive individuals, and this effect, which is 
antagonized by the NO synthase inhibitor NG-monomethyl-
L-arginine (L-NMMA), implicates the L-arginine–NO 
pathway in nebivolol-induced vasodilation (Cockcroft et al 
1995). By preserving endothelial function, nebivolol may 
help to reduce peripheral resistance and arterial stiffness, 
and may ultimately protect against cardiovascular disease 
(Luscher et al 2001).
This open-label pilot study examined the effects of a 
therapeutic dose of nebivolol on forearm blood ﬂ  ow, mea-
sured by plethysmography, and level of inﬂ  ammatory marker, 
in light smokers over a 14-day period.
Methods
Study design
This was an open-label, single-center study that examined the 
efﬁ  cacy and safety of oral nebivolol 5 mg given once daily 
(Figure 1). It was conducted according to the Declaration of 
Helsinki, taking into account the recent version of the German 
Drug Law (AMG), and in accordance with the German 
legal requirements as well as the principles of Good Clini-
cal Practice (GCP). Blood and urine samples were taken on 
Day 1, in overnight-fasted healthy voluteers. Subjects then 
received a standard breakfast and forearm plethysmography 
was performed 2 hours after breakfast. Vital signs and 12-lead 
ECG measurements were taken after plethysmography. Each 
subject then received nebivolol 5 mg (about 3 hours after 
breakfast). Further visits to the study center were scheduled 
on Days 7 and 14 for plethysmography and other efﬁ  cacy 
and safety evaluations, as on Day 1. On Days 2–14, nebivolol 
5 mg was taken at home with breakfast, with the exception 
of days 7 and 14, when nebivolol was taken with breakfast 
at the study center.
Adverse events were recorded by subjects in diaries. 
A ﬁ  nal follow-up examination took place within 8 days of 
the last nebivolol dose.
Study population
Healthy male subjects aged 18–35 years, all of whom were 
light smokers (5 cigarettes/day), were eligible. Written 
informed consent was obtained from all subjects prior to any 
study related procedure. All subjects underwent a physical 
examination up to 7 days prior to enrollment (full medical 
history, 12-lead electrocardiography [ECG], blood pressure, 
heart rate, height and weight, lung function, hematology, 
and urinalysis) and were excluded from the study if they 
exhibited any clinically relevant abnormality. Subjects 
with concomitant illness were excluded from the study, as 
were those subjects with a history of smoking more than 
5 cigarettes per day or who were judged to be heavy smok-
ers according to clinical assessment. Subjects with a forced 
expiratory volume in 1 minute as a percentage of forced vital 
capacity 70% (Tiffenau-Test) at screening were excluded. 
Subjects were also excluded if they were allergic to or had 
contraindications to the study drug or beta-blockers in gen-
eral, were using any prescription or nonprescription drugs, 
or had a history of drug or alcohol abuse.
Study measures
The primary endpoint of this study was the difference in 
forearm blood ﬂ  ow between Day 1 and Day 14 after smoking. 
Secondary endpoints included forearm blood ﬂ  ow differ-
ences between Days 1 and 7, and Days 1 and 14, changes in 
coagulation parameters and high-sensitive-C-reactive protein 
(hs-CRP), as well as safety and tolerability of nebivolol in 
the study population.Vascular Health and Risk Management 2008:4(4) 911
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Forearm plethysmography
Plethysmography recordings (as a surrogate measure of 
endothelial function) were made twice during each outpatient 
visit, before and after smoking a cigarette (Marlboro® regu-
lar strength). The subject rested for 20 minutes in a supine 
position before and after the ﬁ  rst recording. During the last 
10 minutes of the rest period after the ﬁ  rst recording, each 
subject smoked a cigarette and inhaled the smoke. Postsmok-
ing forearm plethysmography was initiated 15 ± 5 minutes 
after the subject had ﬁ  nished smoking the cigarette. Fore-
arm plethysmography was performed in the dominant arm 
according to standard methodology (Whitney 1953; Roddie 
and Wallace 1979). Forearm blood ﬂ  ow was recorded over 
a series of 3-minute measurement periods. Recordings 
taken during the ﬁ  rst minute after wrist cuff inﬂ  ation were 
discarded because of the reﬂ  ex vasoconstriction, and the last 
5 ﬂ  ow recordings of the 3-minute measurement period were 
averaged. The rate of swelling of the forearm was calculated 
from changes of forearm circumference by means of a strain 
gauge placed around the forearm approximately a third of 
the way below the elbow.
Vital signs and ECG
Vital signs (including blood pressure and heart rate) and 
ECG were recorded on Days 1, 7, and 14. Blood pressure 
was measured in a sitting position after 10 minutes of rest. 
Three measurements were taken, with 2 minutes between 
each measurement and the mean value of the last 2 measure-
ments at each visit was recorded.
Blood parameters
Blood samples (3 mL) were taken, placed on ice, and 
shipped to a central laboratory for analysis. Antithrombin 
III , ﬁ  brinogen and serum level of hs-CRP were determined 
using Sarstedt Citrate Monovettes®.
Statistical analysis
The change in forearm blood ﬂ  ow between Days 1 and 14, 
as measured by forearm plethysmography after smoking (the 
primary endpoint), was analyzed by a paired signed rank 
test. As the present study was planned and designed as a 
pilot study, all other efﬁ  cacy and safety data were analyzed 
descriptively and were not subjected to formal statistical 
Figure 1 Study protocol.
Screening Follow-up
Day 1
Assessments performed at Days 1, 7, and 14:
Forearm plethysmography (before and after
cigarette smoking) 
Coagulation parameters
Vital signs (blood pressure, heart rate)
12-lead ECG
Outcome measures
Primary endpoint: Difference in forearm blood flow between Day 1 and Day 14 after smoking.  
Secondary endpoints: Difference in forearm blood flow between Day 1, Day 7, and Day 14 before and
after smoking; changes in coagulation parameters.
Safety analysis:  Vital signs, routine laboratory testing, ECG recording, reporting of adverse events,
Treatment period
Day 7 Day 14
Days 1–14: Nebivolol 5 mg once daily  > Day 21
Adverse events recorded throughout treatment and follow-up periodVascular Health and Risk Management 2008:4(4) 912
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analysis. The primary population for analysis included all 
subjects who received study medication, and who were 
evaluated at a minimum of 2 visits. The safety analysis 
included all subjects who had received at least 1 dose of 
study medication.
Results
Twenty-one subjects were enrolled in the study and 20 
completed the 14-day treatment period. The mean age of 
the study population was 26.2 years, with a body weight 
average of 81.1 kg and a body mass index of 24.8 kg/m2. 
One subject withdrew from the study on Day 12 after 
developing inﬂ  uenza; data from this subject up to Day 
7 were included in the primary and secondary efﬁ  cacy 
and safety evaluations. Another subject developed a sore 
throat on Day 13 of treatment, and as a result, registered 
high hs-CRP levels at Day 14 (47.20 mg/L). Neither of 
the subject withdrawals was considered to be related to 
the study medication.
Forearm plethysmography
The nebivolol-induced change in forearm blood ﬂ  ow after 
smoking between Days 1 and 14 was not signiﬁ  cant (Table 1). 
No statistically signiﬁ  cant nebivolol-induced changes in fore-
arm blood ﬂ  ow were detected between any of the test days, 
either before or after smoking a cigarette (Table 1). On Day 
7 of nebivolol treatment, forearm blood ﬂ  ow after smoking 
was signiﬁ  cantly greater than blood ﬂ  ow before smoking 
(increase of 0.44 mL/min; p = 0.00656; Table 2).
Vital signs and ECG
Mean seated systolic blood pressure (SBP) and diastolic 
blood pressure (DBP) decreased slightly between Day 1 and 
Day 14 (reductions of 3.8 and 2.7 mmHg, respectively). Heart 
rate also decreased from 64.4 bpm on Day 1 to 60.9 bpm on 
Day 14. No clinically signiﬁ  cant ECG changes were found 
for any of the subjects.
Blood parameters
Serum levels of hs-CRP decreased markedly between Day 1 
and Day 14, but there was a high variability among subjects 
(Table 3). No changes were reported in antithrombin III levels 
between Days 1 and 14 (Table 3). Some subjects showed 
pathological antithrombin III values but these were attributed 
to changes in sampling conditions. Fibrinogen values did not 
change between Days 1 and 14.
Safety
Nebivolol was generally well tolerated. In total, 15 adverse 
events were reported in 9 of the 21 subjects. Adverse 
events were mild (13 adverse events [86.6%]) or moderate 
(2 adverse events [13.3%]). Of the 15 adverse events, 9 were 
considered to be possibly related to the study medication. 
The most frequent adverse event, tiredness, was reported 
on 4 occasions. All other adverse events occurred only once 
and included nausea, asthenia, inﬂ  uenza, nasopharyngitis, 
muscle cramps, headache, and sore throat. No deaths or 
serious adverse events were reported and all adverse events 
resolved completely.
Discussion
This study is the ﬁ  rst, to our knowledge, to investigate the 
effects of nebivolol on forearm blood ﬂ  ow in young, nor-
motensive light smokers. Forearm blood ﬂ  ow, assessed by 
plethysmography, was used as a surrogate marker of endo-
thelial dysfunction (Luscher and Noll 1996). The results 
revealed no change in endothelial function between Day 1 
and Day 14. However, between Day 1 and Day 7 of nebivolol 
treatment there was a signiﬁ  cant increase in forearm blood 
ﬂ  ow. There was also no difference in endothelial function 
before or after smoking 1 cigarette, either on the test day (with 
the exception of Day 7) or between 3 consecutive test days 
Table 1 Summary of forearm blood ﬂ  ow changes between Days 
1, 7, and 14, before and after smoking 1 cigarette
   Change  in  blood  ﬂ  ow (mL/min)
 Change  N  Mean  SD
Before smoking  Day 14–Day 1  20  –0.09  1.01
 Day  7–Day  1  21  –0.33  0.80
  Day 14–Day 7  20  0.25  0.75
After smoking  Day 14–Day 1  20  –0.07  1.22
 Day  7–Day  1  21  0.08  1.23
  Day 14–Day 7  20  –0.18  1.39
Table 2 Summary of forearm blood ﬂ  ow before and after smoking 
1 cigarette on Days 1, 7, and 14
 Blood  ﬂ  ow (mL/min)
   N  Mean  SD
Day 1 Before  smoking  21  1.42 0.90
 After  smoking  21  1.45  1.17
  Change   0.03  0.63
Day 7 Before  smoking  21  1.09 0.53
 After  smoking  21  1.53  1.23
  Change   0.44*  0.91
Day 14 Before  smoking 20  1.37  0.74
 After  smoking  20  1.41  0.82
  Change   0.03  0.29
*p = 0.00656.Vascular Health and Risk Management 2008:4(4) 913
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(Days 1, 7, and 14). Nebivolol was well tolerated through-
out the study and exhibited a safety proﬁ  le consistent with 
clinical experience. The slight decrease in blood pressure 
observed over the course of the study is consistent with the 
known antihypertensive proﬁ  le of nebivolol.
The mechanisms of endothelial dysfunction after smok-
ing are complex and heterogeneous (Brunner et al 2005). A 
number of previous studies have linked long-term smoking 
(up to 75 pack years over an individual’s lifetime) with 
endothelial dysfunction – as detected by high-resolution 
ultrasound and physiochemical parameters – which is likely 
to relate to cigarette-induced detrimental effects on ﬂ  ow-
mediated dilation of arteries and the disruption of vessel 
wall morphology (Celermajer et al 1993; Esen et al 2004). 
Cigarette smoke extract has been shown to inhibit the uptake 
of arginine, reduce activity of endothelial NO synthase, 
elevate oxidative stress, and increase levels of asymmetric 
dimethylarginine (ADMA) (Zhang et al 2006). High plasma 
concentrations of ADMA are associated with intima-media 
thickening, left ventricular hypertrophy, and all-cause and 
cardiovascular mortality in patients with end-stage renal 
disease, and to coronary events in males in the general 
population (Zoccali 2006).
Nebivolol is known to relax vascular smooth muscle by 
a mechanism thought to involve stimulation of endothelial 
NO synthase-dependent NO production, which is induced 
by a β2-adrenergic receptor-mediated rise in endothelial Ca2+ 
(Broeders et al 2000). A study in normotensive individuals 
showed that the infusion of nebivolol into the brachial artery 
increased forearm blood ﬂ  ow by 91% (p < 0.01) (Cockcroft 
et al 1995). L-NMMA reduced nebivolol-induced vasodila-
tion by 62%, an effect that was abolished by the NO precursor, 
L-arginine, thereby clearly implicating the L-arginine–NO 
pathway in nebivolol-induced vasodilation (Cockcroft et al 
1995). It should also be noted that the effect of nebivolol 
on ﬂ  ow-mediated dilation of the brachial artery is unique to 
nebivolol and is not a class effect that is shared with other 
beta-blockers. In patients with coronary artery disease, ﬂ  ow-
mediated dilation of the brachial artery was unchanged after 
4 weeks’ treatment with the beta-blocker atenolol, but was 
increased signiﬁ  cantly in patients treated with nebivolol (3.9% 
versus 5.6%; p = 0.041) (Lekakis et al 2005).
The current short-term study shows modest nebivolol-
induced increases in forearm blood ﬂ  ow after smoking at 
all time points measured. This ﬁ  nding may derive from the 
aforementioned ability of nebivolol to stimulate the release 
of NO from endothelial cells and, thereby, elicit vasodila-
tion. Why the effect of nebivolol is only signiﬁ  cant after 
smoking on Day 7 is unclear, but may be attributable to a 
high degree of variability in a small study population. In 
the current study, the difference in forearm blood ﬂ  ow pre- 
and postsmoking was for the most part negligible. Previous 
studies have shown that the smoking-induced attenuation 
in endothelium-dependent vasodilation is maximal shortly 
after initiation of smoking and persists for between 30 and 
50 minutes (Sarabi and Lind 2000). The apparent failure to 
detect signiﬁ  cant changes in forearm blood ﬂ  ow pre- and 
postsmoking in the current study may be attributable to the 
delay in initiating plethysmography (up to 20 minutes after 
smoking). Performing the procedure at a shorter time interval 
postsmoking may be more conducive to detecting maximal 
effects and is worth further investigation.
Previous studies have shown that endothelial dysfunc-
tion in smokers is directly proportional to the lifetime dose 
smoked and is largely reversible in asymptomatic young 
smokers (Celermajer et al 1993; Lind et al 2003). Celermajer 
et al (1993) found that ﬂ  ow-mediated dilation of the brachial 
artery in smokers was inversely related to lifetime dose 
smoked (6.6%, 4.0%, 3.2%, and 2.6% for very light, light, 
moderate, and heavy smokers respectively; p < 0.01). Lind 
et al (2003) examined endothelium-dependent vasodilation, 
measured by forearm plethysmography in 2 groups of appar-
ently healthy subjects with mean ages of 50 and 25 years. In 
the younger subjects, no differences in forearm vasodilation 
were observed between smokers and nonsmokers. In the 
population as a whole, however, endothelium-dependent 
vasodilation showed a signiﬁ  cant inverse relationship with 
duration of smoking (r = –0.52, p < 0.05).
On the basis of these ﬁ  ndings, the young, male, light 
smokers in the current study were unlikely to have chronically 
impaired endothelial function. It is conceivable that the 
vasodilatory effects of nebivolol may be dependent on
the extent of underlying endothelial dysfunction. Examining 
the effects of nebivolol in an older population of smokers 
Table 3 Laboratory data efﬁ  cacy on Days 1 and 14
   N  Mean  SD
Antithrombin III (%)  Day 1  20  94.62  11.49
 Day  14  19  98.78  12.88
  Change   3.83  16.33
Fibrinogen (G/L)  Day 1  20  2.79  0.49
 Day  14  19  2.57  0.40
  Change   –0.25  0.52
hs-CRP (mg/L)  Day 1  19  2.05  1.96
 Day  14  19  1.14  1.51
  Change   –1.04  2.58
Abbreviation: hs-CRP, high-sensitive-C-reactive protein.Vascular Health and Risk Management 2008:4(4) 914
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with a more extensive smoking history (and thus greater 
impairment of endothelial function) may reveal more pro-
nounced effects of nebivolol. The absence of any signiﬁ  cant 
changes in thrombotic activity in this study may also be attrib-
uted to patient population and the duration of the study.
Elevated CRP levels are associated with blunted systemic 
endothelial vasodilator function that is indicative of a sys-
temic inflammatory response (Fichtlscherer and Zeiher 
2000). Acute infection is also known to elevate levels of CRP 
(Ablij and Meinders 2002). The decision to exclude data from 
the subjects in the current study who developed inﬂ  uenza and 
a sore throat is justiﬁ  ed on the basis that inﬂ  ammatory state 
determined by viral agents may transitorily alter endothelial 
function in healthy subjects (Marchesi et al 2005). Normal 
values for CRP range between 0 and 10 mg/L and the inclu-
sion of individual patient data approximately 5 times outside 
the normal range may have led to misinterpretation of the 
CRP result had they been included.
Smoking is known to increase serum CRP levels (Kao 
et al 2006) and, indeed, smoking cessation is recommended 
for those patients with elevated CRP levels (Blake and Ridker 
2002). The signiﬁ  cance of the current marked reduction in 
inﬂ  ammatory markers following treatment with nebivolol 
is consistent with its known role as a vasodilator and is of 
potential clinical importance, particularly as CRP emerges 
as a therapeutic target in the management of cardiovascular 
disease processes (Verma et al 2005).
Conclusions
In summary, the slightly increased forearm blood ﬂ  ow 
after nebivolol treatment at Day 7 and the reduced levels of 
hs-CRP as a measure of inﬂ  ammation suggest that nebivolol 
may have a positive effect on the endothelial function of 
light smokers.
Ultimately, this ﬁ  nding may have important implications 
regarding the selection of antihypertensives on the basis of 
smoking status. An existing study has shown that the effects 
of nebivolol on endothelial function and the prothrombotic 
state were more pronounced in hypertensive smokers than 
in hypertensive nonsmokers (as measured by decreases in 
ﬁ  brinogen, plasminogen activator inhibitor-I, and homocyste-
ine [Vyssoulis et al 2004]). The failure of the beta-blockers, 
celiprolol and carvedilol, to elicit such pronounced effects 
in the same study demonstrates that the ﬁ  nding was unique 
to nebivolol and was not a class effect.
The limited size of the current study limits any ﬁ  rm 
conclusions, but further investigations in a larger and broader 
population are warranted.
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